Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3
2(66.7%)
N/A
1(33.3%)
3Total
Phase 3(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00981058Phase 3Completed

First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin

Role: collaborator

NCT00982111Phase 3Completed

First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin

Role: collaborator

NCT02061917Not ApplicableCompleted

Switching From Usual Brand Cigarettes to a Tobacco-heating Cigarette or Snus

Role: collaborator

NCT01692353Completed

Cardiovascular Disease Biomarkers in Smokers and Moist Snuff Consumers

Role: collaborator

All 4 trials loaded